专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20210069315A1 FLAVIVIRUS VACCINE 有权
公开(公告)号：US20210069315A1
公开(公告)日：2021-03-11
申请号：US16772131
申请日：2018-12-12
申请人： CureVac AG , Sanofi Pasteur
发明人： Patrick BAUMHOF , Wolfgang GROSSE , Edith JASNY , Thomas KRAMPS , Daniel VOSS , Julia DANNENMAIER , Valérie LECOUTURIER , Yves GIRERD-CHAMBAZ
IPC分类号： A61K39/12 , A61P31/14
摘要： The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition. The invention is further directed to a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptide, composition, in particular the first and second medical uses of the immunogenic composition according to the invention.

2. 发明申请

US20210030866A1 VACCINATION IN NEWBORNS AND INFANTS 有权
公开(公告)号：US20210030866A1
公开(公告)日：2021-02-04
申请号：US17067709
申请日：2020-10-11
申请人： CureVac AG
发明人： Karl-Josef KALLEN , Thomas KRAMPS , Margit SCHNEE , Benjamin PETSCH , Lothar STITZ
IPC分类号： A61K39/155 , A61K39/12 , A61K39/145 , A61K47/59 , A61K47/64 , A61K47/69 , A61P31/16 , A61K39/00 , A61K45/06
摘要： The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

3. 发明申请

US20210023199A1 VACCINATION WITH mRNA-CODED ANTIGENS 有权
公开(公告)号：US20210023199A1
公开(公告)日：2021-01-28
申请号：US17067614
申请日：2020-10-09
申请人： CureVac AG
发明人： Karl-Josef KALLEN , Thomas KRAMPS , Margit SCHNEE , Benjamin PETSCH , Lothar STITZ
IPC分类号： A61K39/145 , A61K39/12 , A61K39/00 , A61K45/06 , C12N7/00
摘要： The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

4. 发明申请

US20200268908A1 RABIES VACCINE 审中-公开
公开(公告)号：US20200268908A1
公开(公告)日：2020-08-27
申请号：US16865107
申请日：2020-05-01
申请人： CureVac AG
发明人： Margit SCHNEE , Thomas KRAMPS , Lothar STITZ , Benjamin PETSCH
IPC分类号： A61K48/00 , A61K39/205 , A61K39/12 , A61K9/00 , A61K39/42 , C07K14/005 , C07K16/10 , C12N7/00
摘要： The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof.Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Rabies virus infections. The present invention further describes a method of treatment or prophylaxis of rabies using the mRNA sequence.

5. 发明申请

US20190167782A1 VACCINATION IN NEWBORNS AND INFANTS 审中-公开
公开(公告)号：US20190167782A1
公开(公告)日：2019-06-06
申请号：US16273525
申请日：2019-02-12
申请人： CureVac AG
发明人： Karl-Josef KALLEN , Thomas KRAMPS , Margit SCHNEE , Benjamin PETSCH , Lothar STITZ
IPC分类号： A61K39/155 , A61K39/12 , A61K47/59 , A61K47/64 , A61K39/00 , A61K47/69 , A61P31/16 , A61K39/145 , A61K45/06
摘要： The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

6. 发明申请

US20170218030A1 RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE 审中-公开
公开(公告)号：US20170218030A1
公开(公告)日：2017-08-03
申请号：US15488815
申请日：2017-04-17
申请人： CureVac AG
发明人： Thomas KRAMPS , Margit SCHNEE , Daniel VOSS , Benjamin PETSCH
IPC分类号： C07K14/005 , C07K16/10 , C12N7/00 , A61K39/155
CPC分类号： C07K14/005 , A61K39/12 , A61K39/155 , A61K48/00 , A61K2039/505 , A61K2039/53 , A61K2039/6031 , C07K16/1027 , C07K2317/24 , C12N7/00 , C12N2760/18534
摘要： The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.

7. 发明申请

US20160166678A1 COMBINATION VACCINE 审中-公开
标题翻译：组合疫苗
公开(公告)号：US20160166678A1
公开(公告)日：2016-06-16
申请号：US15048561
申请日：2016-02-19
申请人： CureVac AG
发明人： Karl-Josef KALLEN , Thomas KRAMPS , Margit SCHNEE , Daniel VOSS
IPC分类号： A61K39/155 , C07K14/005 , C12N7/00 , A61K39/145
摘要： The present invention relates to a vaccine, especially a combination vaccine providing at least a first and a second antigenic function, the combination vaccine comprising at least one RNA encoding at least one or more proteins or fragments, variants or derivatives of proteins awarding antigenic function, wherein the first antigenic function being a Fusion (F) protein or a fragment, variant or derivative of a Fusion (F) protein derived from the virus family Paramyxoviridae and the second antigenic function being an Hemagglutinin (HA) protein or a fragment, variant or derivative of an Hemagglutinin (HA) protein derived from the virus family Orthomyxoviridae. Furthermore, the present invention is directed to a kit or kit of parts comprising the components of said combination vaccine and to said combination vaccine for use in a method of prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of infectious diseases like RSV and influenza.
摘要翻译：本发明涉及疫苗，特别是提供至少第一和第二抗原功能的组合疫苗，所述组合疫苗包含至少一种编码至少一种或多种赋予抗原功能的蛋白质或蛋白质的片段，变体或衍生物的RNA，其中所述第一抗原功能是融合（F）蛋白或衍生自所述病毒副副粘病毒科的融合（F）蛋白的片段，变体或衍生物，所述第二抗原功能是血凝素（HA）蛋白或片段，变体或源自病毒科正粘病毒科的血凝素（HA）蛋白衍生物。此外，本发明涉及包含所述组合疫苗的组分和所述组合疫苗的试剂盒或试剂盒，所述组合疫苗用于预防或治疗疾病的方法，特别是预防或治疗感染性疾病如RSV 和流感。

8. 发明申请

US20200155668A1 COMBINATION VACCINE 审中-公开
公开(公告)号：US20200155668A1
公开(公告)日：2020-05-21
申请号：US16781781
申请日：2020-02-04
申请人： CureVac AG
发明人： Karl-Josef KALLEN , Thomas KRAMPS , Margit SCHNEE , Daniel VOSS
IPC分类号： A61K39/155 , A61K39/145 , A61K39/12 , C07K14/005 , C12N7/00
摘要： The present invention relates to a vaccine, especially a combination vaccine providing at least a first and a second antigenic function, the combination vaccine comprising at least one RNA encoding at least one or more proteins or fragments, variants or derivatives of proteins awarding antigenic function, wherein the first antigenic function being a Fusion (F) protein or a fragment, variant or derivative of a Fusion (F) protein derived from the virus family Paramyxoviridae and the second antigenic function being an Hemagglutinin (HA) protein or a fragment, variant or derivative of an Hemagglutinin (HA) protein derived from the virus family Orthomyxoviridae. Furthermore, the present invention is directed to a kit or kit of parts comprising the components of said combination vaccine and to said combination vaccine for use in a method of prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of infectious diseases like RSV and influenza.

9. 发明申请

US20200085942A1 NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT 审中-公开
公开(公告)号：US20200085942A1
公开(公告)日：2020-03-19
申请号：US16541376
申请日：2019-08-15
申请人： CureVac AG
发明人： Thomas KRAMPS , Söhnke VOSS , Jochen PROBST , Ingmar HOERR
IPC分类号： A61K39/39 , C12N15/117 , C07H21/00
摘要： The present invention relates to nucleic acids of the general formula (I): (NuGlXmGnNv)a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant. The present invention furthermore relates to a pharmaceutical composition or to a vaccine, each containing nucleic acids of formula (I) above and/or derivatives thereof as an immunostimulating agent, and optionally at least one additional pharmaceutically active component, e.g. an antigenic agent. The present invention relates likewise to the use of the pharmaceutical composition or of the vaccine for the treatment of cancer diseases, infectious diseases, allergies and autoimmune diseases etc. Likewise, the present invention includes the use of nucleic acids of the general formula (I): (NuGlXmGnNv)a and/or derivatives thereof for the preparation of a pharmaceutical composition for the treatment of such diseases.

10. 发明申请

US20190054164A1 VACCINATION IN NEWBORNS AND INFANTS 审中-公开
公开(公告)号：US20190054164A1
公开(公告)日：2019-02-21
申请号：US16179990
申请日：2018-11-04
申请人： CureVac AG
发明人： Karl-Josef KALLEN , Thomas KRAMPS , Margit SCHNEE , Benjamin PETSCH , Lothar STITZ
IPC分类号： A61K39/155 , A61K47/69 , A61K47/59 , A61K47/64 , A61K39/00 , A61K39/12 , A61K39/145 , A61K45/06
CPC分类号： A61K39/155 , A61K39/00 , A61K39/12 , A61K39/145 , A61K45/06 , A61K47/59 , A61K47/6455 , A61K47/6921 , A61K2039/53 , A61K2039/54 , A61K2039/55 , A61K2039/55583 , A61K2039/572 , A61K2039/575 , A61K2039/6031 , A61K2039/622 , A61P31/16 , C12N2760/16134 , C12N2760/18534 , C12N2760/18571 , Y02A50/412 , Y02A50/486 , Y02A50/487
摘要： The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式